drugset / Trial / NCT02013154
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A study to evaluate the safety and tolerability of DKN-01 in combination with weekly paclitaxel or pembrolizumab in participants with relapsed or refractory Esophagogastric Malignancies
Timeline
- Start
- 2014-05-05
- Primary completion
- 2019-07-19
- Completion
- 2021-01-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DKN-01 | Monoclonal antibody | 150 mg | Intravenous |
| Subject | DKN-01 | Monoclonal antibody | 300 mg | Intravenous |
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |